Detalles de la búsqueda
1.
Benralizumab in severe eosinophilic asthma by previous biologic use and key clinical subgroups: real-world XALOC-1 programme.
Eur Respir J
; 2024 Apr 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-38575162
2.
Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE study.
Respir Res
; 24(1): 135, 2023 May 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-37210543
3.
ChAracterization of ItaliaN severe uncontrolled Asthmatic patieNts Key features when receiving Benralizumab in a real-life setting: the observational rEtrospective ANANKE study.
Respir Res
; 23(1): 36, 2022 Feb 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-35183167
4.
Exacerbation Burden in COPD and Occurrence of Mortality in a Cohort of Italian Patients: Results of the Gulp Study.
Int J Chron Obstruct Pulmon Dis
; 19: 607-618, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38444551
5.
Epidemiology of SLE in Italy: an observational study using a primary care database.
Lupus Sci Med
; 11(1)2024 May 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-38744457
6.
Sustained Effectiveness of Benralizumab in Naïve and Biologics-Experienced Severe Eosinophilic Asthma Patients: Results from the ANANKE Study.
J Asthma Allergy
; 17: 273-290, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38562251
7.
Benralizumab in Patients With Severe Eosinophilic Asthma With and Without Chronic Rhinosinusitis With Nasal Polyps: An ANANKE Study post-hoc Analysis.
Front Allergy
; 3: 881218, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35769575
8.
Clinical Features and Efficacy of Benralizumab in Patients with Blood Eosinophil Count Between 300 and 450 Cells/mm3: A Post Hoc Analysis from the ANANKE Study.
J Asthma Allergy
; 15: 1593-1604, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36387835
9.
Switching from one biologic to benralizumab in patients with severe eosinophilic asthma: An ANANKE study post hoc analysis.
Front Med (Lausanne)
; 9: 950883, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36117962
10.
The Burden of Short-Acting ß2-Agonist Use in Asthma: Is There an Italian Case? An Update from SABINA Program.
Adv Ther
; 38(7): 3816-3830, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-34043208
Resultados
1 -
10
de 10
1
Próxima >
>>